• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cara Therapeutics, Inc. - Common Stock (NQ:CARA)

5.320 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cara Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
February 20, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
January 06, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ARCH on Behalf of Shareholders
December 19, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to Shareholders
December 18, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
December 18, 2024
From Ademi LLP
Via Business Wire
News headline image
Cara Therapeutics Announces Exploration of Strategic Alternatives
July 11, 2024
Piper Sandler & Co. to act as financial advisor 
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
June 12, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Reports First Quarter 2024 Financial Results
May 13, 2024
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
May 06, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
March 07, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
March 04, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
February 12, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
January 22, 2024
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
December 18, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
November 02, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
October 23, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
September 25, 2023
Approval triggers $1.5 million milestone payment to Cara 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Inc. (NASDAQ: CARA) Leading the Way in Friday Trading Based on Percentage Gain
September 15, 2023
Via Investor Brand Network
News headline image
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Reports Second Quarter 2023 Financial Results
August 07, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 03, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in... 
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Reports First Quarter 2023 Financial Results
May 15, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
May 01, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap